Islet Sciences, Inc. Publishes Data Supporting Remogliflozin Etabonate as a Potential Treatment for NAFLD and NASH
May 04, 2015 07:47 ET
|
Islet Sciences, Inc.
RALEIGH, N.C., May 4, 2015 (GLOBE NEWSWIRE) -- Islet Sciences, Inc. (OTCQB:ISLT), a biopharmaceutical company developing new medicines and technologies for the treatment and diagnosis of metabolic...
Islet Sciences, Inc. Presented at 50th International Liver Conference
April 23, 2015 12:02 ET
|
Islet Sciences, Inc.
RALEIGH, N.C., April 23, 2015 (GLOBE NEWSWIRE) -- Islet Sciences, Inc. (OTCQB:ISLT), a biopharmaceutical company developing new medicines and technologies for the treatment of metabolic disease,...
Islet Sciences, Inc. COO to Present at Metabolic Leaders Forum
March 24, 2015 07:55 ET
|
Islet Sciences, Inc.
RALEIGH, N.C., March 24, 2015 (GLOBE NEWSWIRE) -- Islet Sciences, Inc. (OTCQB:ISLT), a biopharmaceutical company developing new medicines and technologies for the treatment of metabolic disease,...
Islet Sciences, Inc. COO to Present at EASL: Remogliflozin Etabonate as Novel Treatment for Non-alcoholic Steatohepatitis (NASH)
March 09, 2015 08:07 ET
|
Islet Sciences, Inc.
RALEIGH, N.C., March 9, 2015 (GLOBE NEWSWIRE) -- Islet Sciences, Inc. (OTCQB:ISLT), a biopharmaceutical company developing new medicines and technologies for the treatment of metabolic disease,...
Islet Sciences, Inc. Confirms Issuance of U.S. Patent for Using SGLT2 Inhibitors to Treat NASH/NAFLD
March 05, 2015 08:07 ET
|
Islet Sciences, Inc.
RALEIGH, N.C., March 5, 2015 (GLOBE NEWSWIRE) -- Islet Sciences, Inc. (OTCQB:ISLT), a biopharmaceutical company developing new medicines and technologies for the treatment of metabolic disease,...
Islet Sciences Enters Into Exclusive License Agreement for Phase 2 SGLT2 Inhibitor Remogliflozin Etabonate
March 03, 2015 09:43 ET
|
Islet Sciences, Inc.
RALEIGH, N.C., March 3, 2015 (GLOBE NEWSWIRE) -- Islet Sciences, Inc. (OTCQB:ISLT), a biopharmaceutical company developing new medicines and technologies for the treatment of metabolic disease,...
Islet Sciences Engages Investment Bank as Financial Advisor
February 09, 2015 08:22 ET
|
Islet Sciences, Inc.
RALEIGH, N.C., Feb. 9, 2015 (GLOBE NEWSWIRE) -- Islet Sciences, Inc. (OTCQB:ISLT) ("Islet Sciences"), a biopharmaceutical company developing new medicines and technologies for the treatment of...
Islet Sciences, Inc. Announces Exclusive Licensing Agreement Between BHV Pharma and Libbs Farmaceutica to Develop and Commercialize SGLT2 Inhibitor Remogliflozin Etabonate
October 06, 2014 08:05 ET
|
Islet Sciences, Inc.
RALEIGH, N.C., Oct. 6, 2014 (GLOBE NEWSWIRE) -- Islet Sciences, Inc. (OTCQB:ISLT), a biopharmaceutical company developing new medicines and technologies for the treatment of metabolic disease,...
Islet Sciences and BHV Pharma Enter Into Merger Agreement; Combined Company to be Named Avogenx, Inc.
October 01, 2014 08:10 ET
|
Islet Sciences, Inc.
RALEIGH, N.C., Oct. 1, 2014 (GLOBE NEWSWIRE) -- Islet Sciences, Inc. (OTCQB:ISLT) ("Islet Sciences"), a biopharmaceutical company developing new medicines and technologies for the treatment of...
Islet Sciences, Inc. Receives Notice of Allowance for U.S. Patent Covering Novel IL-12 Inhibitors
August 06, 2014 08:00 ET
|
Islet Sciences, Inc.
RALEIGH, N.C., Aug. 6, 2014 (GLOBE NEWSWIRE) -- Islet Sciences, Inc. (OTCQB:ISLT), a biopharmaceutical company developing new medicines and technologies for the treatment and diagnosis of metabolic...